SBC Medical Group (NASDAQ:SBC) Announces Earnings Results, Beats Expectations By $0.01 EPS

SBC Medical Group (NASDAQ:SBC) posted its quarterly earnings results on Friday. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.13 by $0.01, FiscalAI reports. The firm had revenue of $39.57 million for the quarter, compared to analyst estimates of $45.19 million. SBC Medical Group had a net margin of 24.28% and a return on equity of 24.17%.

Here are the key takeaways from SBC Medical Group’s conference call:

• Average revenue per customer rebounded to $316 in Q4 (+11% YoY), and management says customer growth and improving unit economics are moving together—management views this as a potential inflection point for long‑term growth.
• Full‑year revenue declined 15% to $174 million, driven by 2024 restructuring and a fee‑structure change in April 2025, indicating material top‑line pressure despite operational actions.
• Profitability strengthened as net income rose 9% to $51 million, EPS increased 4% to $0.50, and EBITDA was $70 million with a 40.4% margin, largely due to the non‑recurrence of prior one‑time listing and revaluation costs.
• Management is rolling out strategic initiatives—SBC Wellness 2.0 (longevity + AI), a multi‑brand dermatology strategy, and early international moves (e.g., OrangeTwist)—which broaden addressable markets but are still early stage.
• Capital policy prioritizes growth and active M&A using abundant cash (with a flexible, approved share buyback program not yet executed), giving the company strategic optionality but no near‑term deployment specifics.

SBC Medical Group Stock Performance

SBC Medical Group stock opened at $3.96 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.10 and a quick ratio of 5.06. The firm’s fifty day moving average price is $4.13 and its 200 day moving average price is $4.04. The company has a market capitalization of $406.22 million, a price-to-earnings ratio of 8.08 and a beta of 1.19. SBC Medical Group has a 12-month low of $2.91 and a 12-month high of $5.75.

Analysts Set New Price Targets

Several research firms have recently issued reports on SBC. Weiss Ratings reissued a “sell (d+)” rating on shares of SBC Medical Group in a research report on Monday, December 29th. BTIG Research began coverage on shares of SBC Medical Group in a report on Friday, March 6th. They set a “buy” rating and a $8.00 target price on the stock. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $8.50.

Insider Transactions at SBC Medical Group

In other SBC Medical Group news, CEO Yoshiyuki Aikawa sold 4,422,900 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $2.12, for a total value of $9,376,548.00. Following the transaction, the chief executive officer directly owned 861,600 shares of the company’s stock, valued at $1,826,592. This represents a 83.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 89.47% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN lifted its holdings in SBC Medical Group by 195.1% in the fourth quarter. Wells Fargo & Company MN now owns 12,626 shares of the company’s stock worth $54,000 after acquiring an additional 8,348 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of SBC Medical Group by 292.0% during the fourth quarter. Russell Investments Group Ltd. now owns 11,775 shares of the company’s stock valued at $51,000 after purchasing an additional 8,771 shares during the last quarter. Barclays PLC raised its position in shares of SBC Medical Group by 123.7% during the 4th quarter. Barclays PLC now owns 17,779 shares of the company’s stock worth $77,000 after purchasing an additional 9,831 shares during the period. Goldman Sachs Group Inc. bought a new stake in shares of SBC Medical Group in the 4th quarter worth approximately $49,000. Finally, Nuveen LLC acquired a new position in SBC Medical Group during the 4th quarter valued at approximately $53,000. 60.82% of the stock is owned by institutional investors and hedge funds.

About SBC Medical Group

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company’s primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.